Skip to content
Wired News Engine – Lifestyle
Author:
BAMBUSA THERAPEUTICS,Inc
Bambusa Therapeutics Presents Positive Preliminary Phase 1 BBT002 Data at American Thoracic Society 2026 (ATS 2026) International Conference and Announces First Patient Dosed in Phase 1b/2a CRSwNP Trial
May 18, 2026
Bambusa Therapeutics Completes Patient Enrollment in the Phase 1b/2a Trial Evaluating BBT001 as a Treatment for Atopic Dermatitis
April 30, 2026
Bambusa Therapeutics Presented Positive Results from the Phase 1 Multiple Ascending Dose Trial of BBT001 at the 2026 American Academy of Dermatology (AAD) Annual Meeting
April 1, 2026
Bambusa Therapeutics Appoints Todd James Chief Financial Officer
March 19, 2026